Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Scribe Therapeutics prices upsized IPO at $15/share, raising $128.7M to advance CRISPR-based genetic medicines.
SNY
$43.89
+$0.10 +0.23%

Scribe Therapeutics prices upsized IPO at $15/share, raising $128.7M to advance CRISPR-based genetic medicines.

Company Fundamentals
23 Jul 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Scribe Therapeutics, a clinical-stage biotech company focused on CRISPR-based genetic therapies, priced its upsized initial public offering at $15 per share, raising approximately $128.7 million before expenses. The shares will begin trading on Nasdaq under the symbol SCTX on July 24, 2026. The company aims to use the funds to develop treatments targeting cardiometabolic diseases, including its lead candidate STX-1150, which reduces LDL cholesterol through epigenetic gene silencing without permanent DNA changes. Scribe also secured a concurrent private placement of 500,000 shares to Sanofi, strengthening its strategic collaborations to accelerate genetic medicine development.

More News (SNY)

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026

Sanofi announced changes to its Executive Committee effective September 1, 2026, aligning leadership across key business areas to support its upcoming strategic priorities. New roles include expanded responsibilities for Finance and Vaccines, with le...

Company Fundamentals
Neutral
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App